Staff shortages, tariffs threaten $350B U.S. pharma investment boom
A new analysis from Global Location Strategies warns that the nation’s biopharma manufacturing boom depends on the availability of skilled labor and regulatory stability.
GLS
A new analysis from Global Location Strategies warns that the nation’s biopharma manufacturing boom depends on the availability of skilled labor and regulatory stability.